<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050279</url>
  </required_header>
  <id_info>
    <org_study_id>LP0133-1409</org_study_id>
    <nct_id>NCT05050279</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People</brief_title>
  <official_title>A Phase 1 Clinical Trial to Evaluate QTcF Prolongation and Proarrhythmic Potential of the Non Antiarrhythmic Drug Delgocitinib Following Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the effects of delgocitinib, taken as a capsule,&#xD;
      on the heart rhythms of healthy people, compared to a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be performed in two parts.&#xD;
&#xD;
        -  Part 1: Group 1 (dose 1 or placebo) and Group 2 (dose 2 or placebo)&#xD;
&#xD;
        -  Part 2: Group 3 (dose 3 or placebo) and Group 4 (dose 4 or placebo)&#xD;
&#xD;
      The doses in Part 2 may be adjusted depending on the results of Part 1.&#xD;
&#xD;
      Participants will be screened within 28 days of their dose. Participants will stay in the&#xD;
      clinic from Day -1 to Day 2 (1 day postdose) and will be dosed on Day 1. A follow up phone&#xD;
      call will take place 2 week (±2 days) after dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">December 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline QTcF (ΔQTcF)</measure>
    <time_frame>predose to 24 hours postdose</time_frame>
    <description>Replicate electrocardiograms (ECGs) (10 ECG replicates) for the determination of ΔQTc interval will be extracted from the continuous digital 12-lead ECG recording</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change from baseline QTcF (ΔΔQTcF)</measure>
    <time_frame>predose to 24 hours postdose</time_frame>
    <description>Replicate electrocardiograms (ECGs) (10 ECG replicates) for the determination of ΔΔQTc interval will be extracted from the continuous digital 12-lead ECG recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Heart Rate (ΔHR)</measure>
    <time_frame>predose to 24 hours postdose</time_frame>
    <description>Replicate electrocardiograms (ECGs) (10 ECG replicates) for the determination of ΔHR interval will be extracted from the continuous digital 12-lead ECG recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected, change from baseline of Heart Rate (ΔΔHR)</measure>
    <time_frame>predose to 24 hours postdose</time_frame>
    <description>Replicate electrocardiograms (ECGs) (10 ECG replicates) for the determination of ΔΔHR interval will be extracted from the continuous digital 12-lead ECG recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Pulse Rate (ΔPR)</measure>
    <time_frame>predose to 24 hourse postdose</time_frame>
    <description>Measurement of PR will be performed manually from electrocardiograms (ECGs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected, change from baseline of Pulse Rate (ΔΔPR)</measure>
    <time_frame>predose to 24 hours postdose</time_frame>
    <description>Measurement of PR will be performed manually from electrocardiograms (ECGs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of QRS interval (ΔQRS)</measure>
    <time_frame>predose to 24 hours postdose</time_frame>
    <description>Measurement of QRS will be performed manually from electrocardiograms (ECGs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected, change from baseline of QRS interval (ΔΔQRS)</measure>
    <time_frame>predose to 24 hours postdose</time_frame>
    <description>Measurement of QRS will be performed manually from electrocardiograms (ECGs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment emergent changes in T-wave morphology.</measure>
    <time_frame>predose to 24 hours postdose</time_frame>
    <description>Measurement of T-wave morphology will be performed manually</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment emergent changes in U-waves presence</measure>
    <time_frame>predose to 24 hours postdose</time_frame>
    <description>Measurement of U-waves presence will be performed manually</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical outliers for QTcF, HR, PR interval, and QRS duration.</measure>
    <time_frame>predose to 24 hours post-dose</time_frame>
    <description>Analysis perfomed for changes in categorical outlines based on treatment emergent adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>dosing to day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Delgocitinib placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delgocitinib capsule (Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delgocitinib capsule (Dose 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delgocitinib capsule (Dose 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delgocitinib capsule (Dose 4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delgocitinib capsule</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>Active dose 1</arm_group_label>
    <arm_group_label>Active dose 2</arm_group_label>
    <arm_group_label>Active dose 3</arm_group_label>
    <arm_group_label>Active dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index of ≥18.0 and &lt;30.0 kg/m2.&#xD;
&#xD;
          -  In good health, as judged by the investigator based on: medical history, physical&#xD;
             examination, vital sign assessment, clinical laboratory evaluations .&#xD;
&#xD;
          -  ECG without any clinically relevant abnormal findings at both screening and baseline&#xD;
&#xD;
          -  No history of additional risk factors for torsades de pointes (for example, heart&#xD;
             failure, hypokalaemia, family history of long QT syndrome).&#xD;
&#xD;
          -  Female subjects of childbearing potential and male subjects with a female partner of&#xD;
             childbearing potential must be willing to use highlly effective methods of&#xD;
             contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disorder which is not stable and could:&#xD;
&#xD;
               -  Affect the safety of the subject throughout the trial.&#xD;
&#xD;
               -  Influence the findings of the trial.&#xD;
&#xD;
               -  Impede the subject's ability to complete the trial.&#xD;
&#xD;
          -  Use of any medication known to prolong the QT/QTc interval within 3 months or 5&#xD;
             half-lives of the drug, whichever is longer, prior to randomisation.&#xD;
&#xD;
          -  Any medications, including St. John's wort, known to chronically alter drug absorption&#xD;
             or elimination processes within 30 days prior to dosing.&#xD;
&#xD;
          -  Current use of combined hormone contraceptives or combined hormonal replacement&#xD;
             therapy.&#xD;
&#xD;
          -  Subjects who have smoked (use of any type of tobacco and nicotine containing products)&#xD;
             within the last 3 months prior to screening.&#xD;
&#xD;
          -  History of chronic alcohol or drug abuse within 12 months prior to screening.&#xD;
&#xD;
          -  Receipt of any vaccine approved for SARS-CoV-2 within 4 weeks prior to baseline and/or&#xD;
             2 weeks after dose.&#xD;
&#xD;
          -  Receipt of live, attenuated vaccines within 4 weeks prior to baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clincal Disclosure</last_name>
    <phone>(+1) 877-557-1168</phone>
    <email>clinicaltrialscontactus@leo-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Labcorp Clinical Research Unit (CRU) Ltd, Springfield House, Hyde Street,</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Ackroyd, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD can be made available to researchers in a closed environment for a specified period of time.</ipd_description>
    <ipd_time_frame>Data is available to request after results of the trial are available on leopharmatrials.com</ipd_time_frame>
    <ipd_access_criteria>Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.</ipd_access_criteria>
    <ipd_url>http://leopharmatrials.com/for-professionals</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

